Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, NY.
Department of Medicine, Division of Nephrology, Baylor College of Medicine, Houston, TX.
Semin Nephrol. 2022 Jan;42(1):29-43. doi: 10.1016/j.semnephrol.2022.01.005.
The continual development of potent immunosuppressive regimens has led to a decreased incidence of acute rejection and improvement of short-term kidney allograft survival. In contrast to acute rejection, glomerular diseases of the kidney allograft are being encountered more frequently and are emerging as leading causes of late kidney allograft failure. Although data on the pathogeneses of glomerular diseases in the kidney allograft are sparse, cumulative evidence suggests that post-transplant glomerular diseases may be the result of inherited predispositions and immunologic triggers. Although studying immunologic signals and performing genome-wide association studies are ideal approaches to tackle glomerular diseases in the kidney allograft, such studies are challenging because of the lack of adequately powered cohorts. In this review, we focus on the most commonly encountered recurrent and de novo glomerular diseases in the kidney allograft. We address the important advances made in understanding the immunopathology and genetic susceptibility of glomerular diseases in the native kidney and how to benefit from such knowledge to further our knowledge of post-transplant glomerular diseases. Defining genomic and immune predictors for glomerular diseases in the kidney allograft would support novel donor-recipient matching strategies and development of targeted therapies to ultimately improve long-term kidney allograft survival.
强效免疫抑制方案的不断发展降低了急性排斥反应的发生率,并改善了短期肾移植的存活率。与急性排斥反应不同,移植肾的肾小球疾病越来越常见,并且成为导致晚期肾移植失败的主要原因。尽管关于移植肾肾小球疾病发病机制的数据很少,但越来越多的证据表明,移植后肾小球疾病可能是遗传易感性和免疫触发因素的结果。尽管研究免疫信号和进行全基因组关联研究是解决移植肾肾小球疾病的理想方法,但由于缺乏足够的大型队列,这些研究具有挑战性。在这篇综述中,我们重点关注移植肾中最常见的复发性和新发肾小球疾病。我们讨论了在理解原发性肾脏肾小球疾病的免疫病理学和遗传易感性方面取得的重要进展,以及如何利用这些知识进一步了解移植后肾小球疾病。确定移植肾肾小球疾病的基因组和免疫预测因子将支持新的供体-受者匹配策略和靶向治疗的发展,最终改善长期肾移植的存活率。